ECSP10010632A - Conjugados del factor ix con vidas medias extendidas - Google Patents
Conjugados del factor ix con vidas medias extendidasInfo
- Publication number
- ECSP10010632A ECSP10010632A EC2010010632A ECSP10010632A ECSP10010632A EC SP10010632 A ECSP10010632 A EC SP10010632A EC 2010010632 A EC2010010632 A EC 2010010632A EC SP10010632 A ECSP10010632 A EC SP10010632A EC SP10010632 A ECSP10010632 A EC SP10010632A
- Authority
- EC
- Ecuador
- Prior art keywords
- factor
- conjugates
- lives
- extended medium
- extended
- Prior art date
Links
- 229960004222 factor ix Drugs 0.000 title abstract 4
- 102100022641 Coagulation factor IX Human genes 0.000 abstract 3
- 108010076282 Factor IX Proteins 0.000 abstract 3
- 108010048049 Factor IXa Proteins 0.000 abstract 1
- 229920000249 biocompatible polymer Polymers 0.000 abstract 1
- 238000011109 contamination Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21022—Coagulation factor IXa (3.4.21.22)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4754408P | 2008-04-24 | 2008-04-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010632A true ECSP10010632A (es) | 2011-02-28 |
Family
ID=41171051
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010632A ECSP10010632A (es) | 2008-04-24 | 2010-11-24 | Conjugados del factor ix con vidas medias extendidas |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20110183906A1 (https=) |
| EP (1) | EP2280734B1 (https=) |
| JP (1) | JP2011519833A (https=) |
| KR (1) | KR20110016440A (https=) |
| CN (1) | CN102046205A (https=) |
| AU (1) | AU2009239641B2 (https=) |
| BR (1) | BRPI0911350A2 (https=) |
| CA (1) | CA2722169A1 (https=) |
| CO (1) | CO6300965A2 (https=) |
| CR (1) | CR11763A (https=) |
| DK (1) | DK2280734T3 (https=) |
| EC (1) | ECSP10010632A (https=) |
| ES (1) | ES2466340T3 (https=) |
| IL (1) | IL208908A0 (https=) |
| MX (1) | MX2010011672A (https=) |
| MY (1) | MY158228A (https=) |
| NI (1) | NI201000177A (https=) |
| NZ (1) | NZ588854A (https=) |
| RU (1) | RU2496521C2 (https=) |
| UA (1) | UA101497C2 (https=) |
| WO (1) | WO2009130602A2 (https=) |
| ZA (1) | ZA201007559B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2670618C (en) | 2006-12-15 | 2016-10-04 | Baxter International Inc. | Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life |
| CN102497884A (zh) | 2009-07-27 | 2012-06-13 | 巴克斯特国际公司 | 凝血蛋白缀合物 |
| KR101912335B1 (ko) | 2009-07-27 | 2018-10-26 | 리폭센 테크놀로지즈 리미티드 | 비혈액 응고 단백질의 글리코폴리시알화 |
| US8642737B2 (en) | 2010-07-26 | 2014-02-04 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| CN106110311A (zh) | 2009-07-27 | 2016-11-16 | 百深公司 | 凝血蛋白缀合物 |
| US8809501B2 (en) | 2009-07-27 | 2014-08-19 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| KR20120061898A (ko) * | 2009-08-20 | 2012-06-13 | 체에스엘 베링 게엠베하 | 출혈성 장애의 치료요법 및 예방 치료에 있어서의 비정맥내 투여를 위한 알부민 융합 응고 인자 |
| GB201007357D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) * | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| UA126265C2 (uk) * | 2010-07-09 | 2022-09-14 | Байовератів Терапьютікс Інк. | Поліпептид фактора іх і спосіб його застосування |
| HUE049352T2 (hu) | 2010-12-22 | 2020-09-28 | Baxalta GmbH | Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására |
| EP3808378A1 (en) * | 2011-05-27 | 2021-04-21 | Baxalta GmbH | Therapeutic proteins with increased half-life and methods of preparing same |
| MY190257A (en) * | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| MX2014015682A (es) * | 2012-06-19 | 2015-07-23 | Polytherics Ltd | Proceso novedoso para preparacion de conjugados de anticuerpo y conjugados de anticuerpo novedosos. |
| TWI750197B (zh) | 2012-09-25 | 2021-12-21 | 美商百歐維拉提夫治療公司 | Ｆｉｘ多肽的應用 |
| AR095527A1 (es) | 2013-03-15 | 2015-10-21 | Biogen Idec Inc | Formulaciones de polipéptido fc-factor ix |
| AR099340A1 (es) * | 2014-02-12 | 2016-07-13 | Novo Nordisk As | Conjugados del factor de coagulación ix |
| EA202092926A3 (ru) | 2014-03-24 | 2021-10-29 | Биовератив Терапьютикс Инк. | Лиофилизированные составы, содержащие фактор ix |
| GB2564389A (en) | 2017-07-04 | 2019-01-16 | Green Running Ltd | A system and method for utility management |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5171569A (en) | 1985-03-15 | 1992-12-15 | National Research Development Corporation | Factor IX preparations uncontaminated by plasma components or pox virus |
| US5268275A (en) | 1991-05-08 | 1993-12-07 | The University Of North Carolina At Chapel Hill | Vitamin K-dependent carboxylase |
| US5621039A (en) * | 1993-06-08 | 1997-04-15 | Hallahan; Terrence W. | Factor IX- polymeric conjugates |
| US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
| WO1999003496A1 (en) | 1997-07-21 | 1999-01-28 | The University Of North Carolina At Chapel Hill | Factor ix antihemophilic factor with increased clotting activity |
| AU3629800A (en) | 1999-03-16 | 2000-10-04 | Children's Hospital Of Philadelphia, The | Enhanced gamma-carboxylation of recombinant vitamin k-dependent clotting factors |
| DE60138364D1 (de) * | 2000-02-11 | 2009-05-28 | Bayer Healthcare Llc | Gerinnungsfaktor vii oder viia konjugate |
| EP1578841B2 (en) * | 2002-12-31 | 2016-10-12 | Nektar Therapeutics AL, Corporation | Maleamic acid polymer derivatives and their bioconjugates |
| WO2004060965A2 (en) * | 2002-12-31 | 2004-07-22 | Nektar Therapeutics Al, Corporation | Hydrolytically stable maleimide-terminated polymers |
| EP1581582B2 (en) * | 2003-01-06 | 2017-06-07 | Nektar Therapeutics | Thiol-selective water-soluble polmer derivatives |
| GB0316294D0 (en) * | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| EP2380985B1 (en) | 2003-09-23 | 2014-01-01 | University of North Carolina at Chapel Hill | Cells expressing vitamin K epoxide reductase and use thereof |
| WO2005033140A1 (ja) * | 2003-09-30 | 2005-04-14 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | 高純度血液凝固ｉｘ因子調製物およびその精製方法 |
| ATE466074T1 (de) | 2003-10-14 | 2010-05-15 | Baxter Int | Vkorc1 (vitamin k epoxide recycling polypeptide), ein therapeutisches ziel für coumarin und deren derivate |
| US20060040856A1 (en) * | 2003-12-03 | 2006-02-23 | Neose Technologies, Inc. | Glycopegylated factor IX |
| KR101146160B1 (ko) * | 2004-06-30 | 2012-07-16 | 넥타르 테라퓨틱스 | 중합체인자 ｉｘ 부분의 접합체 |
| EP1819829A1 (en) | 2004-12-08 | 2007-08-22 | ICOS Corporation | Recombinant method for making multimeric proteins |
| ES2397530T3 (es) | 2005-02-28 | 2013-03-07 | Baxter International Inc. | Coexpresión recombinante de la subunidad 1 de la epóxido reductasa de la vitamina K para mejorar la expresión de proteína dependiente de la vitamina K |
| AU2005329450A1 (en) | 2005-03-15 | 2006-09-28 | University Of North Carolina At Chapel Hill | Methods and compositions for producing active Vitamin K-dependent proteins |
| EP1891231A4 (en) * | 2005-05-25 | 2011-06-22 | Novo Nordisk As | GLYCOPEGYLATED FACTOR IX |
| CA2647314A1 (en) * | 2006-03-31 | 2007-11-08 | Baxter International Inc. | Pegylated factor viii |
| KR20090013816A (ko) * | 2006-05-24 | 2009-02-05 | 노보 노르디스크 헬스 케어 악티엔게젤샤프트 | 연장된 생체내 반감기를 갖는 인자 ⅸ 유사체 |
| JP5737821B2 (ja) * | 2006-08-17 | 2015-06-17 | 一夫 大橋 | 血友病ｂ治療剤及びその製造方法 |
-
2009
- 2009-04-24 WO PCT/IB2009/005763 patent/WO2009130602A2/en not_active Ceased
- 2009-04-24 ES ES09734192.9T patent/ES2466340T3/es active Active
- 2009-04-24 UA UAA201013989A patent/UA101497C2/ru unknown
- 2009-04-24 CN CN200980119877XA patent/CN102046205A/zh active Pending
- 2009-04-24 KR KR1020107026368A patent/KR20110016440A/ko not_active Ceased
- 2009-04-24 MY MYPI2010004993A patent/MY158228A/en unknown
- 2009-04-24 MX MX2010011672A patent/MX2010011672A/es active IP Right Grant
- 2009-04-24 NZ NZ588854A patent/NZ588854A/en not_active IP Right Cessation
- 2009-04-24 DK DK09734192.9T patent/DK2280734T3/da active
- 2009-04-24 CA CA2722169A patent/CA2722169A1/en not_active Abandoned
- 2009-04-24 AU AU2009239641A patent/AU2009239641B2/en not_active Ceased
- 2009-04-24 BR BRPI0911350A patent/BRPI0911350A2/pt not_active IP Right Cessation
- 2009-04-24 JP JP2011505616A patent/JP2011519833A/ja active Pending
- 2009-04-24 EP EP09734192.9A patent/EP2280734B1/en not_active Not-in-force
- 2009-04-24 RU RU2010147813/15A patent/RU2496521C2/ru not_active IP Right Cessation
- 2009-04-24 US US12/989,555 patent/US20110183906A1/en not_active Abandoned
-
2010
- 2010-10-22 NI NI201000177A patent/NI201000177A/es unknown
- 2010-10-22 ZA ZA2010/07559A patent/ZA201007559B/en unknown
- 2010-10-24 IL IL208908A patent/IL208908A0/en unknown
- 2010-10-27 CR CR11763A patent/CR11763A/es not_active Application Discontinuation
- 2010-11-24 CO CO10147494A patent/CO6300965A2/es not_active Application Discontinuation
- 2010-11-24 EC EC2010010632A patent/ECSP10010632A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CR11763A (es) | 2011-04-26 |
| ES2466340T3 (es) | 2014-06-10 |
| KR20110016440A (ko) | 2011-02-17 |
| RU2010147813A (ru) | 2012-05-27 |
| CA2722169A1 (en) | 2009-10-29 |
| US20110183906A1 (en) | 2011-07-28 |
| IL208908A0 (en) | 2011-01-31 |
| AU2009239641A1 (en) | 2009-10-29 |
| BRPI0911350A2 (pt) | 2017-12-05 |
| EP2280734B1 (en) | 2014-02-26 |
| MX2010011672A (es) | 2011-03-02 |
| ZA201007559B (en) | 2012-01-25 |
| WO2009130602A2 (en) | 2009-10-29 |
| NI201000177A (es) | 2011-08-29 |
| AU2009239641B2 (en) | 2013-11-07 |
| CO6300965A2 (es) | 2011-07-21 |
| HK1151986A1 (en) | 2012-02-17 |
| EP2280734A2 (en) | 2011-02-09 |
| UA101497C2 (ru) | 2013-04-10 |
| WO2009130602A3 (en) | 2010-02-11 |
| RU2496521C2 (ru) | 2013-10-27 |
| MY158228A (en) | 2016-09-15 |
| DK2280734T3 (da) | 2014-05-26 |
| NZ588854A (en) | 2011-12-22 |
| WO2009130602A9 (en) | 2010-04-22 |
| CN102046205A (zh) | 2011-05-04 |
| JP2011519833A (ja) | 2011-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010632A (es) | Conjugados del factor ix con vidas medias extendidas | |
| CY1124481T1 (el) | Σταθερα χωρις συντηρητικα μυδριατικα και αντιοξειδωτικα διαλυματα για εγχυση | |
| CR11737A (es) | Polipéptidos modificados del factor ix y usos de los mismos | |
| CL2015003580A1 (es) | Conjugados de suministro de polinucleotidos in vivo que tienen acoplamientos sensibles a enzima. | |
| ECSP10010106A (es) | Trans-clomifeno para el síndrome metabólico | |
| BR122020010601B8 (pt) | conjugados de proteína-oligossacarídeo, seus usos, e composições farmacêuticas | |
| UY31785A1 (es) | Sistema polimerico de lagrimas artificiales | |
| MX2018013333A (es) | Composiciones de nucleasas terapeuticas y metodos. | |
| ECSP13013097A (es) | Coagonistas del receptor de glucagón/glp-1 | |
| CL2012001094A1 (es) | Una silla que posee una sección base con uno o mas elementos de patas, una sección de asiento, un primer y segundo mecanismo para proporcionar un movimiento de rotación y un movimiento de deslizamiento lateral respectivamente al asiento, donde ambos mecanismos se activan de manera independiente del el estado de activación del otro. | |
| CR20120019A (es) | Composicion de insulina de accion prolongada | |
| JO3026B1 (ar) | مستضادات ببتيد شبيه الجلوكاجون - 2 | |
| EA201491934A1 (ru) | Аналоги глюкагоноподобного пептида-2 (glp-2) | |
| UY31543A1 (es) | Sistema de administracion de rnai de interferencia y usos del mismo | |
| CO6670520A2 (es) | Lactmas sustituidas con piperidinio como moduladores de gpr119 | |
| BR112013029256A8 (pt) | combinação farmacêutica para uso no tratamento de pacientes com diabetes tipo 2 | |
| MX361155B (es) | Cocleatos hechos con fosfatidilserina de soja. | |
| MX341778B (es) | Goma de mascar natural incluyendo materiales de celulosa. | |
| EA201590617A1 (ru) | Композиции алкилированного циклодекстрина и способы их получения и применения | |
| BR112015009603A2 (pt) | novos derivados de pirazina | |
| ECSP14023048A (es) | Agentes terapéuticos para administración subcutánea optimizados | |
| MX2018003685A (es) | Moleculas tipo esfingolipidos sinteticas, farmacos, metodos de su sintesis y metodos de tratamiento. | |
| DOP2010000327A (es) | Utilizacion de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento de nivel de creatinina debido a la administracion de dronedarona | |
| BRPI1011630B8 (pt) | paracetamol para a administração parenteral | |
| CL2014002430A1 (es) | Uso del compuesto r-p88 (metabolito activo de iloperidona en su forma enantiomerica r) para tratar una enfermedad psiquiatrica tal como esquizofrenia, trastorno bipolar, depresion, autismo, entre otras, cuando se administra una vez al dia; y composicion farmaceutica que comprende el compuesto r-p88. |